Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Current Deferred Revenue (2021 - 2023)

InMed Pharmaceuticals has reported Current Deferred Revenue over the past 3 years, most recently at $28656.0 for Q4 2023.

  • For Q4 2023, Current Deferred Revenue rose 77.21% year-over-year to $28656.0; the TTM value through Dec 2023 reached $28656.0, up 77.21%, while the annual FY2023 figure was $16171.0, N/A changed from the prior year.
  • Current Deferred Revenue for Q4 2023 was $28656.0 at InMed Pharmaceuticals, up from $16171.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $28656.0 in Q4 2023 and troughed at $8390.0 in Q4 2021.
  • A 3-year average of $15737.3 and a median of $16171.0 in 2022 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 92.74% in 2022 and later skyrocketed 77.21% in 2023.
  • Year by year, Current Deferred Revenue stood at $8390.0 in 2021, then skyrocketed by 92.74% to $16171.0 in 2022, then skyrocketed by 77.21% to $28656.0 in 2023.
  • Business Quant data shows Current Deferred Revenue for INM at $28656.0 in Q4 2023, $16171.0 in Q2 2023, and $16171.0 in Q1 2023.